Novelion 
Welcome,         Profile    Billing    Logout  
 3 Products   50 Diseases  3 Products   19 Trials   779 News 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Juxtapid (lomitapide) / Novelion, Chiesi
2018-002911-80: Study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome Studio per valutare sicurezza, tollerabilità ed efficacia di Lomitapide per il trattamento di pazienti affetti da Sindrome Chilomicronemica Familiare

Ongoing
3
20
Europe
Lojuxta, [C10AX12 Codice ATC], [C10AX12 - Codice ATC], Lojuxta
PRM|21218, Amryt Pharma, Amryt Pharmaceuticals DAC
Familial Chylomicronemia Syndrome Sindrome Chilomicronemica Familiare, Familial hypercholesterolemia is a rare inherited disease that causes high levels of cholesterol in the blood and serious cardiovascular consequences. L'ipercolesterolemia familiare è una rara malattia ereditaria che causa elevati livelli di colesterolo nel sangue e gravi conseguenze cardiovascolari., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2019-002278-30: A clinical trial to assess the safety and effect of the drug lomitapide in the treatment of children with the condition Homozygous Familial Hypercholesterolaemia (HoFH) who are on Stable Lipid-lowering Therapy

Not yet recruiting
3
45
Europe
Lomitapide 2mg hard capsules, [PRD7255830], [PRD7255977], [PRD7256003], [Lomitapide 2mg hard capsules], Capsule, hard, Lojuxta 5 mg hard capsules, Lojuxta 10 mg hard capsules, Lojuxta 20 mg hard capsules
Amryt Pharmaceuticals DAC, Amryt Pharmaceuticals DAC
Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European population., A condition that runs in families (homozygous familial hypercholesterolaemia or HoFH), which leads to the patient having very high cholesterol from a very early age., Body processes [G] - Metabolic Phenomena [G03]
 
 
NCT04681170 / 2019-002278-30: Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Completed
3
46
Europe, RoW
Lomitapide
Amryt Pharma, Amryt Pharmaceuticals DAC
Homozygous Familial Hypercholesterolaemia (HoFH)
10/22
06/24
LILITH, NCT06832371: Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients with Homozygous Familial Hypercholesterolemia

Recruiting
N/A
72
Europe
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi), Amryt Pharmaceuticals DAC, Clinical Trial Consulting, CMV-Stat S.r.l.
Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), Dyslipidemia
12/26
12/26
NCT02135705: LOWER: Lomitapide Observational Worldwide Evaluation Registry

Checkmark 1-year data from LOWER registry in HoFH at NLA 2016
May 2016 - May 2016: 1-year data from LOWER registry in HoFH at NLA 2016
Recruiting
N/A
300
Europe, Canada, US, RoW
Lomitapide, Juxtapid, Lojuxta
Amryt Pharma
Homozygous Familial Hypercholesterolemia
03/28
09/28
Myalept (metreleptin) / Novelion
NCT06484868: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
4
12
Europe
Metreleptin
Amryt Pharma
Partial Lipodystrophy
02/28
02/28
NCT04026178: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Active, not recruiting
4
10
US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalized Lipodystrophy
10/24
04/25
APG-20 OLE, NCT06679270: Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
3
15
US
Metreleptin
Amryt Pharma
Familial Partial Lipodystrophy
03/28
03/28
NCT06548100: A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

Recruiting
3
8
US
mibavademab, REGN4461
Regeneron Pharmaceuticals
Generalized Lipodystrophy
03/27
07/27
NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Recruiting
3
15
Europe
Metreleptin
Amryt Pharma
Generalized Lipodystrophy
09/26
09/26
METRE-PL, NCT05164341: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Recruiting
3
65
Europe, Canada, US, RoW
metreleptin, Placebo
Amryt Pharma
Partial Lipodystrophy
06/25
01/26
NCT02262832: Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

Recruiting
3
30
US
Metreleptin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lipodystrophy, Diabetes, Hyperlipidemia
07/27
07/27
2017-003014-22: Leptin in hepatic lipid metabolism in humans Leptin und der Leberfettsoffwechsel

Ongoing
2
43
Europe
Myalept, Concentrate and solvent for solution for injection, Myalept
Medical University of Vienna, Medical University of Vienna
lipodystrophy patients, patients after liver transplantation and healthy controls, patients suffering from partial or total disease of fat storage in adipose tissue patients with liver transplanthealthy controls, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT00085982: Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

Active, not recruiting
2
11
US
Metreleptin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Severe Insulin Resistance
10/19
01/30
NCT05351164: Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Active, not recruiting
2
4
US
Metreleptin
University of Michigan, Amryt Pharma
Lipomatosis, Multiple Symmetrical
04/24
10/28
METRAN, NCT06305182: Metreleptin in Anorexia Nervosa

Recruiting
2
50
Europe
Metreleptin, Myalept®, Sodium chloride
Gabriella Milos
Anorexia Nervosa
08/26
08/26
NCT02262806: Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

Active, not recruiting
2
29
US
Metreleptin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Lipodystrophy, Hyperlipidemia
07/27
07/27
NCT02404896: Expanded Access Metreleptin Study

Available
N/A
US
Metreleptin, MyaLept
University of Michigan
Familial Partial Lipodystrophy
 
 
NCT00691158: A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

Active, not recruiting
N/A
10
US
Pramlintide (Amylin), Amylin, Placebo (Normal Saline), Placebo, 2 Metreleptin, Leptin, Leptin plus Pramlintide, Leptin and Amylin
Oregon Health and Science University
Obesity
07/24
07/24
NCT05419037: Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

Recruiting
N/A
90
US
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lipodystrophy
03/26
03/26
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry

Recruiting
N/A
100
Europe, US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalised Lipodystrophy, Partial Lipodystrophy
10/31
10/31
QLT091568 / Novelion
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Juxtapid (lomitapide) / Novelion, Chiesi
2018-002911-80: Study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome Studio per valutare sicurezza, tollerabilità ed efficacia di Lomitapide per il trattamento di pazienti affetti da Sindrome Chilomicronemica Familiare

Ongoing
3
20
Europe
Lojuxta, [C10AX12 Codice ATC], [C10AX12 - Codice ATC], Lojuxta
PRM|21218, Amryt Pharma, Amryt Pharmaceuticals DAC
Familial Chylomicronemia Syndrome Sindrome Chilomicronemica Familiare, Familial hypercholesterolemia is a rare inherited disease that causes high levels of cholesterol in the blood and serious cardiovascular consequences. L'ipercolesterolemia familiare è una rara malattia ereditaria che causa elevati livelli di colesterolo nel sangue e gravi conseguenze cardiovascolari., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2019-002278-30: A clinical trial to assess the safety and effect of the drug lomitapide in the treatment of children with the condition Homozygous Familial Hypercholesterolaemia (HoFH) who are on Stable Lipid-lowering Therapy

Not yet recruiting
3
45
Europe
Lomitapide 2mg hard capsules, [PRD7255830], [PRD7255977], [PRD7256003], [Lomitapide 2mg hard capsules], Capsule, hard, Lojuxta 5 mg hard capsules, Lojuxta 10 mg hard capsules, Lojuxta 20 mg hard capsules
Amryt Pharmaceuticals DAC, Amryt Pharmaceuticals DAC
Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European population., A condition that runs in families (homozygous familial hypercholesterolaemia or HoFH), which leads to the patient having very high cholesterol from a very early age., Body processes [G] - Metabolic Phenomena [G03]
 
 
NCT04681170 / 2019-002278-30: Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Completed
3
46
Europe, RoW
Lomitapide
Amryt Pharma, Amryt Pharmaceuticals DAC
Homozygous Familial Hypercholesterolaemia (HoFH)
10/22
06/24
LILITH, NCT06832371: Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients with Homozygous Familial Hypercholesterolemia

Recruiting
N/A
72
Europe
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi), Amryt Pharmaceuticals DAC, Clinical Trial Consulting, CMV-Stat S.r.l.
Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), Dyslipidemia
12/26
12/26
NCT02135705: LOWER: Lomitapide Observational Worldwide Evaluation Registry

Checkmark 1-year data from LOWER registry in HoFH at NLA 2016
May 2016 - May 2016: 1-year data from LOWER registry in HoFH at NLA 2016
Recruiting
N/A
300
Europe, Canada, US, RoW
Lomitapide, Juxtapid, Lojuxta
Amryt Pharma
Homozygous Familial Hypercholesterolemia
03/28
09/28
Myalept (metreleptin) / Novelion
NCT06484868: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
4
12
Europe
Metreleptin
Amryt Pharma
Partial Lipodystrophy
02/28
02/28
NCT04026178: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Active, not recruiting
4
10
US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalized Lipodystrophy
10/24
04/25
APG-20 OLE, NCT06679270: Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
3
15
US
Metreleptin
Amryt Pharma
Familial Partial Lipodystrophy
03/28
03/28
NCT06548100: A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

Recruiting
3
8
US
mibavademab, REGN4461
Regeneron Pharmaceuticals
Generalized Lipodystrophy
03/27
07/27
NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Recruiting
3
15
Europe
Metreleptin
Amryt Pharma
Generalized Lipodystrophy
09/26
09/26
METRE-PL, NCT05164341: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Recruiting
3
65
Europe, Canada, US, RoW
metreleptin, Placebo
Amryt Pharma
Partial Lipodystrophy
06/25
01/26
NCT02262832: Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

Recruiting
3
30
US
Metreleptin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lipodystrophy, Diabetes, Hyperlipidemia
07/27
07/27
2017-003014-22: Leptin in hepatic lipid metabolism in humans Leptin und der Leberfettsoffwechsel

Ongoing
2
43
Europe
Myalept, Concentrate and solvent for solution for injection, Myalept
Medical University of Vienna, Medical University of Vienna
lipodystrophy patients, patients after liver transplantation and healthy controls, patients suffering from partial or total disease of fat storage in adipose tissue patients with liver transplanthealthy controls, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT00085982: Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

Active, not recruiting
2
11
US
Metreleptin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Severe Insulin Resistance
10/19
01/30
NCT05351164: Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Active, not recruiting
2
4
US
Metreleptin
University of Michigan, Amryt Pharma
Lipomatosis, Multiple Symmetrical
04/24
10/28
METRAN, NCT06305182: Metreleptin in Anorexia Nervosa

Recruiting
2
50
Europe
Metreleptin, Myalept®, Sodium chloride
Gabriella Milos
Anorexia Nervosa
08/26
08/26
NCT02262806: Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

Active, not recruiting
2
29
US
Metreleptin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Lipodystrophy, Hyperlipidemia
07/27
07/27
NCT02404896: Expanded Access Metreleptin Study

Available
N/A
US
Metreleptin, MyaLept
University of Michigan
Familial Partial Lipodystrophy
 
 
NCT00691158: A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

Active, not recruiting
N/A
10
US
Pramlintide (Amylin), Amylin, Placebo (Normal Saline), Placebo, 2 Metreleptin, Leptin, Leptin plus Pramlintide, Leptin and Amylin
Oregon Health and Science University
Obesity
07/24
07/24
NCT05419037: Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

Recruiting
N/A
90
US
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lipodystrophy
03/26
03/26
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry

Recruiting
N/A
100
Europe, US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalised Lipodystrophy, Partial Lipodystrophy
10/31
10/31
QLT091568 / Novelion
No trials found

Download Options